Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-149-7_7

Chapter 7: Targeted and Surface-Engineered Nanocarriers: Precision Therapy in Alzheimer's disease

Saurabh Bhardwaj1*

[1*]*Sharda School of Pharmacy, Sharda University Agra, U.P, India, Pin-282007*
Saurabh.bhardwaj5234@gmail.com
Corresponding Author
Saurabh Bhardwaj
Email: Saurabh.bhardwaj5234@gmail.com

Abstract

Alzheimer's disease (AD) is a progressive neurological disorder, poses considerable treatment hurdles due to its complicated pathophysiology and the strong blood-brain barrier (BBB), which restricts central nervous system (CNS) medication delivery. Conventional medicines merely provide symptomatic alleviation and do not prevent disease development. Nanocarrier-based precision medicine provides a breakthrough approach by allowing for tailored, sustained, and brain-penetrant medication delivery systems. This chapter delves into the wide range of nanocarrier platforms developed for Alzheimer's treatment, including lipid-based carriers, polymeric nanoparticles, dendrimers, inorganic nanoparticles, and hybrid systems.

Surface engineering technologies such as ligand functionalization, receptor-mediated targeting (e.g., transferrin, LRP1, insulin receptors), PEGylation, and biomimetic cloaking are investigated for their contributions to improved specificity, BBB penetration, and biocompatibility. The chapter focuses on the mechanisms by which nanocarriers cross the blood-brain barrier, undergo cellular absorption, and accomplish intraneuronal drug release while also assisting in the clearance of pathogenic aggregates such as amyloid-beta and hyperphosphorylated tau.

Preclinical studies show that customized nanocarriers improve cognitive results and diminish pathology indicators in Alzheimer's disease models. Emerging clinical trials have promising translational potential, but issues such as long-term safety, manufacturing scalability, and regulatory approval remain. The combination of personalized therapy through biomarker and genetic targeting, as well as AI-driven design and theranostic capabilities, provides new opportunities for enhancing nanocarrier efficacy. Overall, surface-engineered nanocarriers show great potential in altering therapy paradigms for Alzheimer's disease by providing precision-targeted, minimally invasive, and multifunctional treatment options.

Keywords: *Alzheimer's disease, neurodegenerative, blood-brain barrier, nanocarrier-based*

1. Introduction

1.1 The outline of Alzheimer's Disease (AD)

Alzheimer's disease (AD) is the most general kind of dementia and a significant worldwide public-health concern (WHO, 2025). In 2021, Approximately 57 million individuals globally lived with dementia, with 60% residing in low- and middle-income countries, and approximately 10 million new cases were diagnosed each year (WHO, 2025). Globally, an estimated 55 million people suffer from dementia, with the number expected to rise to 78 million by 2030 and 139 million by 2050 [1] [2]**.** Specifically, around 35 million of these 55 million have AD [3].

In the United States, over 7.2 million people aged 65 and up are expected to have Alzheimer's disease by 2025, with nearly three-quarters being 75 or older a demographic trend that is mirrored around the world [4]. The prevalence in the United States is estimated to be around 11% among those aged 65 and up, rising to 33% in those aged 85 and up. Women face a disproportionate burden, accounting for two-thirds of American AD patients.

Despite a minor decrease in age-adjusted incidence in some countries, the overall number of patients is increasing owing to population aging. Alzheimer's disease has a significant impact in 2022, Alzheimer's-related fatalities will have more than quadrupled from 2000, making it the sixth largest cause of death in those aged 65 and above in the United States. Dementia care costs in the US are projected to reach $384 billion in 2025 and $1 trillion by 2050. In addition, over 12 million Americans offer unpaid care worth US$413.5 billion [5].

Alzheimer's disease persists to be a tough therapeutic enemy. Interventions licensed through the US Food and Drug Administration (FDA), chiefly cholinesterase inhibitors and NMDA receptor antagonists, can only provide symptomatic relief and cannot arrest disease progression [6]. Two of the most significant barriers are the blood-brain barrier (BBB), which rejects around 98% of small-molecule medicines, and virtually all biologics, as well as drug resistance, low brain bioavailability, and acute systemic toxicity. These shortcomings highlight the critical need for novel delivery platforms capable of safe and effective CNS targeting.

1.2 The rationale behind nanocarrier-based precision therapy

1.2.1 Importance of Targeted Drug Delivery

Precision medication delivery requires targeting therapy directly to damaged tissues in order to optimize benefit while minimizing collateral harm. Nanocarriers (engineered materials sized 1-100 nm) provide fine control for passive and active targeting [7]. These carriers can be dynamically changed to show ligands, antibodies, or peptides that exploit receptor-mediated transcytosis across the BBB, allowing administration into the central nervous system.

Recent advancements demonstrate the potential of such systems. For example, in mice, a dual-peptide-functionalized polymeric nanocarrier efficiently transported an anti-inflammatory substance (an IRAK4 inhibitor) across the blood-brain barrier, significantly increasing appetite and muscle mass. These discoveries have implications for inflammatory central nervous system disorder, along with Alzheimer's disease [8]. Similar systems have passed the blood-brain barrier to deliver therapeutic proteins and nucleic acids, expanding the toolkit for treating neurodegeneration [9].

1.2.2 Advantages over conventional systems

Nanocarriers provide a variety of advantages:

1. **Enhanced BBB penetration**
   Surface engineering allows receptor-mediated transcytosis—which uses transferrin, insulin, and LDL receptors to easily traverse the BBB [10].
2. **Optimized pharmacokinetics**
   The mononuclear phagocyte system cannot clear particles smaller than 100 nm efficiently. Polyethylene glycol (PEG) coatings enhance circulatory half-life while decreasing immune recognition [11].
3. **Payload versatility**
   Nanocarriers are versatile vehicles that can carry tiny compounds, peptides, proteins, nucleic acids, and even CRISPR complexes [12].
4. **Surface Functionalization**
   Targeting moieties such as antibodies, aptamers, or peptides, can be used to improve selectivity and cellular absorption.
5. **Stimulus-responsive release**
   Responsive systems activated by pH, enzymes, temperature, or magnetic fields allow for precise, on-site drug delivery [13].
6. **Theranostic capabilities**
   Nanocarriers can co-deliver therapeutic drugs with imaging probes (such as gold nanorods), allowing for real-time monitoring of therapy efficacy and biodistribution [14].

Collectively, these traits address significant shortcomings of traditional formulations poor brain access, quick clearance, and off-target toxicity while allowing next-generation CNS therapies.

1.3 Scope of the Chapter

This chapter investigates targeted, surface-engineered nanocarriers as precision therapeutics for Alzheimer's disease, using the following framework:

- **Nanocarrier platforms:** Comprehensive examination of lipid-based systems (e.g., liposomes, solid lipid nanoparticles), polymeric particles (e.g., PLGA,

dendrimers), inorganic carriers (e.g., gold, cerium oxide), and hybrid composites.

- **Surface-engineering strategies:** A review of ligand attachment techniques (peptides, antibodies, aptamers), receptor-targeting (transferrin, insulin, LRP proteins), stealth coatings (PEGylation), stimuli-responsive and biomimetic changes such as cell-membrane cloaking.
- **Delivery mechanisms:** A discussion of BBB transcytosis (adsorptive versus receptor-mediated) as well as intracellular release and clearance of problematic aggregates upon uptake.
- **Efficacy and translation:** A summary of preclinical animal models, early-stage clinical initiatives, related translational problems, and regulatory implications.
- **Future Outlooks:** Future plans include research into safety and toxicity, scale-up and manufacturing challenges, chronic stability, tailored techniques (such as biomarker-genomics-based targeting), integration with theranostics and AI, and existing regulatory frameworks.

This comprehensive introduction contextualizes the need for innovative delivery techniques, describes the promise of nanocarrier systems, and prepares readers for the advancements and problems that will be discussed in the following chapters.

2. Pathophysiology of Alzheimer's Disease Relevant to Nanocarrier Targeting

2.1 Amyloid-Beta (Aβ) Plaque Formation

Amyloid-beta (Aβ) peptides accumulate extracellularly in Alzheimer's disease (AD), lead to the production of senile plaques in the cortex and hippocampus. β and γ secretases degrade amyloid precursor protein (APP) to form peptides with 40 or 42 amino acid residues. When Aβ is misfolded due to aberrant cleavage or overproduction, it forms fibrils, oligomers, protofibrils, and eventually insoluble plaques.

The amyloid cascade theory suggests that excessive Aβ buildup, either by overproduction or inadequate clearance, leads to tau pathology, neuroinflammation, synaptic loss, along with neurodegeneration [15]. Genetic mutations in APP, presenilin-1, and presenilin-2 lead to crisis of the aggregation-prone Aβ42 form, resulting in familial early-onset Alzheimer's disease. In sporadic Alzheimer's disease, the clearance is reduced by the APOE4 allele, leading to an increase in Aβ burden over time [16].

Soluble Aβ oligomers are reorganized as powerful neurotoxins that go beyond physical plaques. synapse loss and neuronal death caused by them through interference with synaptic plasticity, decreasing long-term potentiation, generating oxidative stress, and disrupting calcium homeostasis. Amyloid plaques are surrounded by microglia and astrocytes, which produce pro-inflammatory cytokines, worsening neurotoxicity and facilitating the spread of the plaque [17].

The treatment with nanocarriers focuses on Aβ as a strategic target. Nanoparticles can be designed with ligands, antibodies, or aptamers to bind Aβ oligomers or fibrils and to localize to plaques, allowing for diagnostic imaging and therapeutic administration. Fibrillization can be inhibited by gold nanoparticles with Aβ-binding peptides, while plaque formation can be directly disrupted by polymeric carriers containing Aβ-clearing enzymes or kinase inhibitors [18].

2.2 Tau Protein Hyperphosphorylation and Neurofibrillary Tangles

Concurrently, tau protein, a microtubule-associated protein required for axonal stability and transport, is hyperphosphorylated intracellularly in AD. Tau hyperphosphorylates, splits from microtubules, and aggregates into paired helical and straight filaments in illness, After all building neurofibrillary tangles (NFTs) inside neurons.

The buildup of NFTs is strongly linked to cognitive deterioration, probably more than the load of Aβ plaques. Tau illness is progressed in a predictable fashion across brain regions, demonstrating active spread via extracellular tau seeds. Synaptic function is impaired, mitochondrial integrity is altered, and neuronal death is caused by tau aggregates [19].

Tau-targeting nanocarrier approaches include vehicles containing tau phosphorylation inhibitors, tau-targeted siRNA, and antisense oligonucleotides. Furthermore, extracellular tau seeds can be intercepted by nanocarriers loaded with tau-binding peptides or antibodies, inhibiting interneuronal spread. In preclinical models, for example, polymeric nanoparticles coated with anti-tau antibodies were preferentially targeted to brain areas with high tau load, allowing for targeted administration and possibly clearance [20].

2.3 Neuroinflammation and Oxidative Stress

Aβ and tau abnormalities enhance neuroinflammation and oxidative stress, ultimately leading to neuronal degeneration. Chronic activation of microglia and astrocytes around Aβ plaques and NFTs leads to a chronic inflammatory milieu with elevated levels of cytokines such IL-1β, TNF-α, and IL-6 [21]. Persistent inflammation reduces phagocytic clearance of Aβ, increases tau phosphorylation via kinase activation, and promotes synaptic disintegration [22].

Oxidative stress is induced by mitochondrial malfunction, aberrant metal ion balance, and the formation of reactive oxygen species (ROS) via Aβ. ROS damages membranes, proteins, and nucleic acids, causing apoptosis and impairing neuronal function. Increased lipid peroxidation, protein carbonylation, and DNA damage are common indications of Alzheimer's disease [23].

Nanocarriers can be engineered to deliver anti-inflammatory, antioxidant, and gene-silencing substances directly to neuroinflammatory sites. Nanoparticles containing resveratrol or curcumin, both potent anti-inflammatory and antioxidant compounds,

have been shown to increase CNS transport across the BBB and lower neuroinflammatory biomarkers in Alzheimer's disease mice models [24]. Dendrimer-based systems containing siRNA targeting pro-inflammatory cytokines, as well as nanocarriers with surface changes that allow for absorption by active microglia, can further control inflammatory cascades while reducing systemic exposure.

2.4 Dysfunction of Blood–Brain Barrier (BBB)

The blood-brain barrier is a closely controlled interface made up of endothelial cells, pericytes, astrocyte end-feet, and tight junction complexes that govern macromolecular interaction between circulation and the central nervous system. In AD, increasing BBB failure develops early even before overt cognitive symptoms and manifests itself as leaking of plasma proteins, diminished tight junction integrity, and altered transporter function [25].

BBB disruption can cause neuronal damage by allowing neurotoxic chemicals to enter, compromising clearance systems (e.g., Aβ efflux), inducing vascular inflammation, and lowering nutrition availability [26]. Furthermore, decreased BBB function is associated with rapid cognitive decline and disease progression.

From a therapeutic approach, BBB failure has two implications: it inhibits the delivery of most therapeutic medicines while also providing chances for nanocarrier penetration if correctly engineered. Nanoparticles smaller than 100 nm that have been appropriately PEGylated and surface-functionalized with receptor ligands (e.g., transferrin, insulin, or LRP1 ligands) can enter cells through receptor-mediated transcytosis. Notably, targeting receptors such as low-density lipoprotein receptor-related protein 1 (LRP1) and transferrin receptor (TfR) has been shown to significantly improve CNS uptake [27]. Nanocarriers can effectively bypass BBB restrictions by imitating endogenous transport processes.

2.5 Targetable Biomarkers and Receptors in AD

Effective nanocarrier targeting relies on finding cellular and molecular markers that are selectively overexpressed or significantly enriched in AD-affected tissues or cells. Several critical receptors and biomarkers are being actively investigated:

- **TfR (The transferrin receptor):** TfR which is expressed on brain endothelial cells and neuronal surfaces is widely used for BBB transcytosis. Nanocarriers coupled with transferrin or anti-TfR antibodies demonstrate considerably enhanced brain delivery and neuronal uptake.
- **Insulin receptor (IR):** It can be found on both endothelial and neuronal cells in the central nervous system. IR-targeted nanocarriers demonstrate potential BBB crossing and increased uptake.

- **LRP1 (low-density lipoprotein receptor related protein 1):** LRP1, a clearance receptor during Aβ, is expressed in the BBB and neurons, serving a dual role of promoting entrance and helping in Aβ clearance.
- **SR-BI (Scavenger receptor class B type 1):** Expressed on brain endothelium and astrocytes, utilized by HDL-mimicking nanocarriers to improve CNS targeting and engage lipoprotein-mediated transport pathways.
- **Aβ- and tau-specific ligands:** Nanoparticles can be conjugated with aptamers, peptides, or antibody fragments to bind Aβ oligomers/fibrils or tau aggregate and localize them to plaques or NFTs.
- **Inflammatory markers:** AD-associated vasculature upregulates molecules such as ICAM-1, VCAM-1, and selectins. Nanocarriers built with antibody fragments against these markers can selectively attach to inflamed areas and deliver anti-inflammatory payload.

Nanocarriers can be dual- or multi-targeted by selectively combining targeting moieties, such as TfR + Aβ-binding peptide to cross the BBB and home to plaques, or LRP1 + anti-inflammatory ligand to enter inflamed tissue and control cytokine signaling. These multifunctional designs promote specificity, therapeutic effectiveness, and safety by decreasing off-target effects and enhancing payload delivery to diseased foci [28].

3. Nanocarrier Systems for Alzheimer's Therapy

Nanocarrier-based therapeutic approaches have surfaced as viable alternatives to standard Alzheimer's disease (AD) medications characterized by poor permeability across blood brain barrier and low bioavailability of drug. Nanocarrier technologies like lipid-based system and hybrid multifunctional ones enable target delivery of tiny molecules and neuroprotective drugs into afflicted brain regions. Many nanocarrier systems related to Alzheimer's disease precision treatment are discussed in this manuscript with considerable thoroughness nowadays.

3.1 Lipid-Based Nanocarriers

Lipid-based carriers feature prominently among nanocarriers researched for central nervous system administration owing largely to biocompatibility and high drug loading capacity.

3.1.1 Liposomes

Spherical vesicles comprising phospholipids by layer envelop an aqueous core pretty much everywhere inside liposomes remarkably structured with great specificity. Structural similarity with brain membrane enables fairly successful biocompatibility and interaction across blood brain barrier quite effectively. Liposomes get functionalized

pretty easily with polyethylene glycol for somewhat prolonged circulation and ligands like lectoferrin help cross blood brain barrier [29].

Antioxidants and antiamyloid chemicals are delivered fairly effectively via liposomes quite open nowadays in various experimental setups and studies rivastigmine-loaded liposomes coupled with transferring significantly enhanced blood brain barrier penetration thereby prolonging cognitive improvement in animal models of Alzheimer's disease. Liposomes serve as gene and siRNA carriers targeting amyloid precursor protein or hyperphosphorylated tau proteins pretty effectively nowadays.

3.1.2 Solid Lipid Nanoparticles (SLNs)

Solid lipid nanoparticles are tiny carriers comprising solid lipids held together rather tenuously by various surfactant molecules. Labile medications receive physical stability and protection via regulated release. Lipohillic antioxidant and neuroprotective chemicals supposedly benefit most from SLNs. Quercetin-loaded SLNs have been shown to elevate brain bioavailability remarkably in alzhimer disease models while decreasing markers of oxidative stress notably. ApoE or transferin modification of SLNs surfaces remarkably improves targeting Aβ plaques effectively with quite surprising outcomes generally.

3.1.3 NLCs (Nanostructured Lipid Carriers)

NLCs are second-generation lipid carriers that combine solid and liquid lipids to increase drug loading and decrease crystallinity. They reportedly outperform SLNs significantly in encapsulation efficiency and sustained release usually under certain circumstances.

3.2 Polymeric Nanocarriers

Polymeric nanocarriers are adaptable systems made up of biodegradable and biocompatible polymers such as PLGA (poly (lactic-co-glycolic acid), PEG (polyethylene glycol), and PAMAM (polyamidoamine) dendrimers. The changeable surface elements enable active targeting and regulated medicine release.

3.2.1 Polymeric Nanoparticles (PLGA, PEGylated Systems)

The FDA has authorized PLGA nanoparticles as carriers for controlled medication release. When combined with PEG (PEGylation), longer systemic circulation and decreased opsonization are obtained.

PLGA nanoparticles loaded with donepezil or memantine and surface-modified with lactoferrin or transferrin have enhanced cognitive recovery in animal models of Alzheimer's disease due to greater BBB penetration. PLGA systems can deliver neurotrophic factors or siRNA to decrease APP or BACE1 genes, thereby decreasing Aβ generation [30].

3.2.2 Dendrimers

Dendrimers are nanoscale macromolecules whose surface can be altered extensively with various functional groups and chemical properties somehow. Multivalent surfaces facilitate conjugation of medicine tailored ligands and imaging agents rather effectively owning largely to inherent versatility. PAMA dendrimers have been successfully loaded with antioxidant like M-acetyl cysteine which diminishes neuroinflammation significantly in AD mouse models [31].

3.3 Inorganic Nanocarriers

Inorganic nanoparticles offer distinct benefits like greatly increased surface-to-volume ratio and highly changeable optical properties for imaging purposes somehow.

3.3.1 Gold Nanoparticles (AuNPs)

Gold nanoparticles exhibit anti-amyloidogenic properties binding pretty tightly to Aβ peptides and largely inhibiting formations of fibrils. AuNPs can carry Aβ-targeting ligands or siRNA, and anti-tau antibodies, enabling multifaceted diagnostic applications and novel therapeutic interventions simultaneously. Surface modification with PEG and certain ligands targeting blood brain barrier can significantly enhance CNS dilevery of their payloads effectively [32]. .

3.3.2 Cerium Oxide Nanoparticles (Nanoceria)

Cerium oxide nanoparticles possess inherent antioxidant capabilities by redox cycling between Ce3+ and Ce4+.thereby scavenging reactive oxygen species effectively. It has been shown that nanoceria protects neurons from oxidative stress while also improving memory function [33]. BBB penetration is enhanced by functionalization with peptides or lipids.

3.4 Hybrid and Multifunctional Nanocarriers

Hybrid nanocarriers combine the properties of lipidic, polymeric, and inorganic systems to provide synergistic outcomes. Examples include liposome-polymer hybrids, lipid-coated gold nanoparticles, and polymer-inorganic nanoconjugates.

Multifunctional nanocarriers can include dual ligands (e.g., transferrin + Aβ antibody) for active targeting, co-encapsulate several medications (e.g., anti-Aβ + antioxidant), and combine imaging and therapeutic agents for theranostics [34].

PEGylated PLGA nanoparticles coated in lipid and functionalized with anti-tau antibodies adequately target tau tangles and Aβ plaques, foremost to improved cognitive outcomes in AD rats.

3.5 Comparison of various nanocarrier platforms

Table 7.1: The table below summarizes the key characteristics of the major nanocarrier systems used in AD therapy

Nanocarrier Type	Average Size (nm)	Targeting Potential	Drug-Loading Efficiency	Advantages	Limitations
Liposomes	80–200	High (ligand-functionalized: TfR, ApoE)	Moderate–High	Biocompatible; appropriate for hydrophilic and lipophilic medicines.	Limited stability, leakage risk
SLNs	50–180	Moderate (ApoE, transferrin functionalization)	Moderate	Controlled release, stable	Lower drug-loading compared to NLCs
NLCs	80–200	High (surface-modified with ligands)	High	High encapsulation and sustained release	More complex formulation
PLGA NPs	100–250	High (PEG, TfR, lactoferrin functionalization)	High	FDA-approved, controlled release	Requires surfactants, slower degradation
Dendrimers	5–20	Very High (multi-ligand conjugation)	Very High	Multivalency, targeted delivery	Potential cytotoxicity at higher concentrations
Gold NPs	10–100	High (Aβ antibody or peptide conjugation)	Moderate	Anti-amyloidogenic, imaging potential	Accumulation danger; long-term safety uncertain.

Cerium Oxide NPs	5–50	Moderate	Moderate	Antioxidant, neuroprotective	Limited clinical data
Hybrid Systems	Variable (50–200)	Very High (dual/multifunctional targeting)	High	Theranostic potential, synergistic action	Complex manufacturing, regulatory hurdles

Nanocarriers provide a breakthrough approach to Alzheimer's treatment by increasing medication bioavailability, allowing BBB penetration, and delivering targeted and multifunctional delivery. Lipid-based systems are frequently employed because to their safety, whilst polymeric and dendrimer-based carriers provide high drug loading and selective targeting. Inorganic nanocarriers have unique imaging and antioxidant capabilities, whereas hybrid systems offer both therapeutic and diagnostic advantages.

As surface engineering and ligand conjugation develops, these nanocarriers show great potential for clinical use in precision AD treatment.

4. Surface Engineering Strategies for Targeted Delivery

Surface engineering of nanocarriers is crucial to obtaining precise medication delivery for Alzheimer's disease (AD). Modifying nanocarrier surfaces with ligands, antibodies, aptamers, and stimuli-responsive coatings can improve blood-brain barrier (BBB) penetration, increase specific binding to pathological targets like amyloid-beta (Aβ) plaques or tau tangles, and improve drug bioavailability with minimal off-target toxicity.



Figure 7.1 – Conceptual Illustration (Description)

Chapter discusses the most common surface engineering methodologies, including as ligand-based targeting, receptor-mediated transport, stimuli-responsive alterations, stealth technologies, and current breakthroughs in biomimetic systems.

4.1 Ligand-Based Targeting

Ligand-based targeting includes functionalizing nanocarriers with particular ligands that preferentially bind to targets over expressed in AD pathology, such as Aβ plaques, tau proteins, or BBB endothelial receptors.

4.1.1 Peptides (TGN, RVG29, Angiopep-2)

Peptides are commonly employed because they are tiny, highly selective, and easy to chemically conjugate.

- **TGN peptide:** TGN, derived from phage display, promotes BBB penetration via receptor-mediated transcytosis. In AD mouse models, TGN-modified PEG-PLGA nanoparticles loaded with curcumin significantly increased brain accumulation and reduced Aβ.
- **RVG29 peptide**: RVG29, derived from the rabies virus glycoprotein, binds neuronal cells' nicotinic acetylcholine receptors (nAChRs). RVG29-conjugated nanoparticles can efficiently transport siRNA or small medicines to neurons.
- **Angiopep-2:** Targets the low-density lipoprotein receptor-related protein 1 (LRP1), which is over expressed in BBB endothelial cells and neurons. Angiopep-2 modified nanoparticles improve brain uptake and target Aβ plaques [35].

4.1.2 Antibodies and Antibody Fragments (Anti-Aβ, Anti-Tau)

Monoclonal antibodies or their fragments can be coupled to nanocarriers to achieve high specificity:

- Anti-Aβ antibodies help localize plaques and remove Aβ fibrils or oligomers more effectively.
- Anti-tau antibodies inhibit tau aggregation and interneuronal proliferation.

Nanocarriers functionalized with antibody fragments (Fab or scFv) are recommended for increased BBB penetration due to their smaller molecular size [36].

4.1.3 Aptamers

Aptamers are short single-stranded DNA or RNA oligonucleotides that form distinct 3D structures with high target affinity. Aβ- or tau-specific aptamers conjugated to nanoparticles improve selective binding and targeted drug delivery, with minimal immunogenicity compared to antibodies.

4.2 Receptor-Mediated Targeting

Receptor-mediated transcytosis (RMT) is the most effective ways to transport nanocarriers across the BBB.

4.2.1 Transferrin Receptor (TfR) Targeting

TfR is heavily expressed on BBB endothelial cells. Nanoparticles coupled with transferrin or anti-TfR antibodies pass the blood-brain barrier via endocytosis. TfR-based targeting has effectively delivered Aβ-clearing enzymes and siRNAs.

4.2.2 Insulin Receptor (IR) Targeting

Insulin receptor is another important BBB transporter. Nanocarriers laced with insulin or anti-IR antibodies boost brain transport significantly, especially of neuroprotective peptides and certain growth hormones [37].

4.2.3 LRP (Low-Density Lipoprotein Receptor-Related Protein) Targeting

LRP1 plays a vital function in clearing Aβ from the BBB quite effectively. LRP-mediated targeting leverages various ligands such as Angiopep-2, lactoferrin, and ApoE-derived peptides penetrating the blood-brain barrier and localizing Aβ plaques deeply.

4.3 Stimuli-Responsive Surface Modifications

Smart nanocarriers disperse pharmaceuticals rapidly in response to unique biochemical causes with Alzheimer's disease microenvironments very effectively nowadays.

4.3.1 pH-Responsive Coatings

Neuroinflammation coupled with lysosomal breakdown generates fairly acidic microenvironments within the Alzheimer's disease brain tissue pretty frequently nowadays. Polyhistidine and similar polymers sensitive extremely to pH enable release of medication in environments surprisingly acidic and remain fairly stable systematically.

4.3.2 Enzyme-Responsive Systems

Overexpression of enzymes, including MMPs and β-secretase links fairly and directly to Alzheimer's disease pathogenesis. Site-specific medication release in sick areas is made possible by enzyme-cleavable linkers (such as MMP-sensitive peptides) coupled to nanocarriers [38].

4.4 PEGylation and Stealth Properties

PEGylation is the process of coating a surface with polyethylene glycol (PEG), which acts as a hydrophilic shield, allowing it to avoid the mononuclear phagocyte system and extend circulation half-life [39]. However, excessive PEGylation may impair receptor binding, needing a careful balance.

4.5 Recent Advances in Biomimetic and Cell-Membrane-Coated Nanocarriers

To inherit immune-evasive and BBB-penetrating capabilities, biomimetic procedures entail covering nanoparticles with natural cell membranes [40].

Neutrophil membrane-coated nanoparticles have been shown to enhance accumulation in inflamed brain regions, while macrophage membrane-coated systems improve Aβ phagocytosis in AD [41]. Hybrid systems that combine cell membranes with targeted ligands (such as RVG29 or Angiopep-2) are cutting-edge methods to precision treatment.

Table 7.1 – Summary of Surface Engineering Strategies for AD Nanocarriers

Strategy	Examples	Target/Mechanism	Advantages	Limitations
Peptide Ligands	TGN, RVG29, Angiopep-2	BBB receptors (TfR, nAChRs, LRP1)	High BBB penetration, small size	Potential immunogenicity
Antibodies/Fragments	Anti-Aβ, Anti-tau	Plaques & tangles	High specificity	High cost, limited BBB penetration (full IgG)
Aptamers	Aβ- or tau-specific	Plaques, tau aggregates	Low immunogenicity, high specificity	Rapid nuclease degradation
RMT Targeting	TfR, IR, LRP ligands	BBB transcytosis	Efficient brain uptake	Competition with endogenous ligands
Stimuli-Responsive	pH-sensitive, enzyme-	Acidic/enzymatic microenvironment	Controlled drug release	Complex formulation

	cleavable			
PEGylation	PEG chains	Prolonged circulation	Reduced clearance	Excess PEG may limit targeting.
Biomimetic	Cell-membrane coated NPs	Inflammation sites, immune evasion	High biocompatibility	Large-scale production challenges



Figure 7.2 – Surface Engineering Approach for Targeted Delivery in AD

5. Mechanisms of Brain Targeting and Cellular Uptake

Achieving precision therapy for Alzheimer's disease (AD) requires an understanding of how tailored nanocarriers are able to perforate the blood–brain barrier (BBB) and how therapeutic cargo is released intracellularly.

5.1 Crossing the Blood–Brain Barrier (BBB)

Blood-brain barrier exhibit selective permeability basically defending brain from myriad potentially noxious chemicals whilst allowing crucial nutrients right through. Closely packed endothelial cells construct this barrier prohibiting most chemicals from passing freely through it with considerable effectiveness usually. Therapeutic drugs face a formidable hurdle crossing blood brain barrier especially once used for treating Alzheimer diseases rather insidiously. Nanocarrier transport across blood brain barrier occurs via two basic mechanisms namely adsorptive- mediated trancytosis and receptor-mediated transcytosis basically through cellular processes.

5.1.1 Adsorptive-Mediated Transcytosis

Negatively charged endothelial cell membranes interact with positively charged nanoparticles triggering adsorptive-mediated transcytosis suddenly across cellular boundaries. Electrostatic interactions fuel procedure largely and get amplified by some changes on nanocarriers surface pretty significantly. Effectiveness of this transport mechanism can be markedly improve by using cationic polymers [42].

Table 7.2: Comparison of Transcytosis Mechanisms

Mechanism	Description	Advantages	Limitations
Adsorptive-Mediated	Involves electrostatic interactions with cell membranes.	Simple modification of carriers	Limited to tiny, positively charged particles.
Receptor-Mediated	Uses particular receptors on endothelial cells.	High Specificity and efficiency	Requires knowledge of target receptors.

5.1.2 Receptor-Mediated Transcytosis

In particular receptors on blood-brain barrier endothelial cells are attached to by nanocarriers where receptor-mediated transcytosis is an additional selective approach. This unique technique is considered crucial for the movement of larger molecules such as peptides and proteins, which can't penetrate the blood brain barriers by passive diffusion. Transferrin and insulin receptors are two most common receptors entangled in this process actually with rather significant consequences normally. Distribution of Therapeutic drug directly into brain tissue can be markedly improved by developing nanocarriers cleverly mimicking natural ligands of receptors [43].

5.2 Intraneuronal Drug Release and Pathological Aggregate Removal

Nanocarriers having breached blood brain barrier efficiently next hurdle entails effectuating release of medication into target neurons whilst clearing pathological Alzhimer's disease associated aggregates like amyloid-beta plaques and tau tangles.

5.2.1 Intraneuronal Drug Release

Therapeutic effectiveness of nanocarriers largely hinges on release of drugs into complex intraneuronal drug environments. Several unorthodox methods have been conducted for achieving highly regulated sustained release of pharmaceuticals deep into neurons over time. A particular approach entails employing nanocarriers sensitive to pH levels which release cargo rapidly inside acidic endosomes or lyososomal compartments. Medicine gets delivered right where it needs to work maximising therapeutic potential pretty effectively at point of action basically [44].

5.2.2 Clearance of Pathological Aggregates

Clearing abnormal protein aggregates rapidly becomes crucial somehow for treating alzheimer's disease nasty symptoms with highly varying success rates. Nanocarriers can be cleverly engineer incorporating enzymes or unusual small compounds facilitating breakdown of amyloid-beta proteins and tau proteins simultaneously. Absorption of therapeutic drugs by neurons can be ramped up via application of nanocarriers allowing for pretty efficient action in neuronal aggregates. Tailored distribution of such medicines significantly lowers plaque load in animal models of Alzheimer's disease remarkably well under certain conditions.



Figure 7.3: Pathways for Drug Release and Aggregate Clearance

6. Preclinical and clinical Evidence

6.1 Key Preclinical Studies in Animal Models

Preclinical studies play a crucial role for determining the effectiveness and safety of nanocarriers before tested on humans. Some Various animal models of Alzheimer's disease have been utilized to assessment the potential of these nanocarriers for the delivery of therapeutic medicines to the brain, study revealed.

6.1.1 Nanocarrier Types and Their Efficacy

Liposomes, polymeric nanoparticles, and dendrimers a variety of nanocarriers have been focused through Preclinical investigations.



Figure 7.3: Sharp features that may be adapted to therapeutic application

1. **Liposomes:** It has been found that hydrophilic and hydrophobic medicines can be successfully encapsulated by them. Study revealed that liposomes are spherical vesicles built up of lipid bilayers. Liposomal curcumin formulations may drastically lower amyloid-beta levels in a transgenic mouse model of AD, resulting in improved cognitive performance.

2. **Polymeric nanoparticles:** PLGA nanoparticles were utilized by to deliver methylene blue, an anti-amyloid agent. The results indicated a considerable decline in amyloid plaque load and enhanced memory function in treated mice**.**

3. **Dendrimers:** Branching macromolecules called dendrimers can be modified to deliver certain substances. Dendrimer-based nanocarriers loaded with small interfering RNA (siRNA) targeting the tau protein dramatically decreased tau phosphorylation in a tauopathy rat model, according to a research by **[45]**, indicating a possible treatment option for tau-related disorders.

Table 7.3: Overview of Important Preclinical Research

Study Reference	Nanocarrier Type	Therapeutic Agent	Model Used	Key Outcomes
(Zhang et al. 2020)	Liposomes	Curcumin	Transgenic mouse model	Enhanced cognition and decreased amyloid-beta levels
(Kumar et al. 2021)	Polymeric nanoparticles	Methylene blue	Model of AD mouse	Reduced plaque load and improved memory performance
(Lee et al. 2022)	Dendrimers	tau-targeting siRNA	Model of tauopathy in mice	enhanced neuronal health and decreased tau phosphorylation

6.2 Ongoing Clinical Trials Involving Nanocarriers for AD

Numerous clinical studies are being conducted to evaluate the safety and effectiveness of nanocarrier-based treatments for Alzheimer's disease as the area of nanomedicine develops. The goal of these trials is to apply preclinical research to clinical settings.

6.2.1 Notable Clinical Trials

- **NANOBRAIN Study:** In this current Phase I study, individuals with mild to moderate AD are being studied to assess the safety and tolerability of a new liposomal formulation of the cholinesterase inhibitor donepezil. In comparison to conventional formulations, preliminary findings indicate enhanced absorption and decreased adverse effects.

- **NANO-AD Study:** In this Phase II study, patients with early-stage AD are being evaluated for the effectiveness of polymeric nanoparticles coated with anti-amyloid antibodies. The change in amyloid plaque levels as determined by PET imaging over a six-month period is the main outcome.

- **DENDRIMER-AD Study:** The goal of this experiment is to deliver neuroprotective medicines to AD patients using dendrimer-based nanocarriers. Promising safety profiles and possible cognitive advantages are shown by early data [46].

6.2.2 Challenges in Clinical Translation

There are still a number of obstacles in the way of the clinical use of nanocarrier treatments for Alzheimer's disease, even with the encouraging outcomes of preclinical research. These consist of:

- ❖ **Patient Heterogeneity:** Finding appropriate patient populations for clinical trials is made more difficult by the vast range of symptoms and rates of development that Alzheimer's disease displays.

- ❖ **Regulatory Obstacles:** Nanomedicine approval is a difficult procedure that necessitates a large amount of safety and effectiveness evidence. The clearance procedure is problematic as regulatory bodies sometimes do not have clear rules for nanocarrier items [47]**.**

- ❖ Manufacturing & Scalability: It can be difficult to increase output while preserving consistency while producing nanocarriers, which must adhere to strict quality control requirements.

6.3 Regulatory and Translational Challenges

There are several translational and regulatory obstacles in the way of developing nanocarrier treatments for Alzheimer's disease from the bench to the bedside. Comprehending these obstacles is essential to the effective creation of these novel treatments.

6.3.1 Regulatory Framework

Although it is changing, the regulatory environment around nanomedicines is still complicated. While precise laws for nanocarriers are still being advanced, the EMA (European Medicines Agency) and the U.S. FDA (Food and Drug Administration) have released instructions for the advancement of nanomedicines. Crucial things to think about are:

- ➢ **Characterization:** For regulatory approvals, a thorough investigation of the nanocarrier's dimensions, form, surface charge, and drug release characteristics is deemed necessary.

- ➢ **Safety Assessment:** the possible toxicity of nanocarriers must be carefully considered, taking into account both their long-term effects and interactions with biological systems, taking into account both their long-term effects and interactions with biological systems [48].

6.3.2 Translational Challenges

Converting from preclinical results into clinical practice there are many barriers:

- **Efficacy in Humans:** Human reactions are not usually anticipated by results from animal models. Due to the multifaceted nature of Alzheimer's disease and the complexity of human biology treatment results may vary.

- **Long-Term Research:** Long term care is needed for Alzheimer's disease because it is a chronic illness. Clinical studies must be planned to evaluate the long-term safety and effectiveness of nanocarrier therapeutics, which can require a significant amount of time and resources.

Alzheimer's disease has enormous abilty to enhance treatment results by the creation of surface-engineered and targeted nanocarriers.

7 Challenges and Future Perspectives

Surface-engineered nanocarriers specifically tailored for Alzheimer's disease opens up numerous opportunities for significant therapeutic advancement quite rapidly nowadays. Proper integration of these technologies into clinical practice must be ensured and several gnarly obstacles must be addressed meanwhile somehow. Possibilities for bespoke medicinal techniques and issues with mass production and stability as well as safety concerns and AI-driven nanocarrier design integration with theranostics are discussed.

7.1 Safety and Toxicity Concerns

Safety and toxicity remain paramount concerns when nanocarriers are being developed for medication delivery especially in Alzheimer's disease contexts where patients already face heightened risk due to advanced age and concomitant health issues. Distinct characteristics of various nanocarriers including size shape and quirky surface chemistry might weirdly affect interactions with biological systems and potentially lead to very negative consequences.

7.1.1 Biocompatibility and Biodistribution

Safe usage of nanocarriers in people must be ensured by Biocompatibility. According to various studies certain nanocarriers can cause inflammatory reactions and organ toxicity alongside cytotoxicity. Cationic nanoparticles potentially can cause more harm owing partly due to interactions with cell membranes through they’re remarkably adapt at breaching blood-brain barrier.

7.1.2 Long-Term Effects

Regarding long-term effects of deploying nanocarriers are much remains murky. Cumulative toxicity from chronic exposure to nanoparticles remains a distinct possibility for assessing safety profiles. Nanocarriers altering biological functioning or triggering obscure immunological reactions necessitates thorough investigation pretty much now it seem utterly necessary.

7.2 Large-Scale Manufacturing and Stability Issues

Broad scale Production of nanocarriers poses several formidable challenges simultaneously in setting beyond typical labs with rather complex requirements. Nanocarrier formulations ought to be remarkably stable garnering regulatory approvals fairly quickly and they are pretty darn reproducible in most clinical trials.

7.3 Genomic & Biomarker-based targeting (Personalized Medicine Approach)

Like genetic profiles or biomarkers might supplant existing Alzheimer's disease treatments entirely through customized medicine involving treatment tactics tailored rather specifically around individual patient characteristics. When relevant medications land squarely in hands of correctly identified patients, Efficacy of nanocarrier-based therapeutics increases sharply.

7.4 Integration with Theranostics and AI-Driven Nanocarrier Design

Integrating theranostics and artificial intelligence into nanocarrier design nowadays gets cited rather frequently as potentially advancing Alzheimer's disease therapy. Theranostics combines diagnostic facets with therapeutic ones enabling assessment of efficacy in real-time under a given treatment regimen effectively.

7.4.1 Theranostic Nanocarriers

Theranostic nanocarriers stealthily dispatch therapeutic payloads while amassing diagnostic data from diverse bodily locales very effectively.

7.4.2 AI-Driven Design

Nowadays Machine learning approaches and artificial intelligence have potential to significantly enhance design and optimization of nanocarriers profoundly. Various biological systems by analyzing vast amounts of information rapidly through AI spots trends and makes predictions about nanocarrier interaction. According to Speeding up design processes enables development of more effective safe nanocarrier formulations pretty quickly.

Conclusions

Alzheimer's disease is a complicated neurodegenerative ailment marked by progressive cognitive deterioration and memory loss. Recent advancements in precision nanomedicine for treating Alzheimer's disease are covered here alongside possibilities

of such technology being analyzed thoroughly nowadays. Novel therapeutic approaches have been demanded largely owing to multifaceted Alzheimer's disease and brain drug delivery being notoriously problematic. Surface-engineered nanocarriers have emerged rather promisingly as precision medicine technique in Alzheimer's disease with ability for markedly improving therapeutic efficacy.

Acknowledgement

The authors would like to express their sincere gratitude to *Deep Science Publisher* and the editorial team of this book for their invaluable support in the final publication process and for providing the opportunity to contribute to this esteemed volume.

Conflicts of Interest

The authors declare that there are no conflicts of interest related to this work.

Funding Source

No funding was received for the preparation of this book chapter.

Author Contribution

All authors have contributed equally to the conception, preparation, and completion of this book chapter.

References

1. Alzheimer’s disease International. Dementia: global impact and regional variation. London: ADI; 2020.
2. World Health Organization. Dementia fact sheet. Geneva: WHO; 2025 Mar.
3. Zhong S, et al. The global burden of Alzheimer’s disease and other dementias: 1991–2021. Glob Public Health. 2025;10:1585711.
4. BrightFocus Foundation. Alzheimer’s disease: facts & statistics [Internet]. 2025 [cited 2025 Aug 29]. Available from: https://www.brightfocus.org.
5. Alzheimer’s Association. Alzheimer’s disease facts and figures 2025. Chicago (IL): Alzheimer’s Association; 2025.
6. Wikipedia. Alzheimer’s disease [Internet]. 2025 [cited 2025 Aug 29]. Available from: https://en.wikipedia.org/wiki/Alzheimer%27s_disease
7. Jalili C, et al. Brain-targeting nanocarriers loaded with resveratrol in AD therapy. J Nanobiotechnol. 2023;21(1):45.
8. Axios. OSU reports “breakthrough” in nanoparticle cancer treatment. Axios. 2025 Apr 21.

9. Muolokwu CE, et al. Functionalized nanoparticles to deliver nucleic acids to the brain. Front Pharmacol. 2024;15:1405423.
10. Liu J, et al. The blood–brain barriers: novel nanocarriers for central nervous system drug delivery. J Nanobiotechnol. 2025;23:27.
11. Kamath AP. Revolutionizing neurotherapeutics: nanocarriers unveiling phytochemical delivery in AD. Neurosci Rev. 2024;12:112–35.
12. Song X, et al. Advantages of nanocarriers for basic neurological research. J Basic Nanomed. 2023;8(2):113–25.
13. Prencipe G, et al. PEG branched polymer for functionalization of nanomaterials. arXiv. 2009.
14. Niu X, et al. Nanocarriers: powerful vehicles to overcome blood–brain barrier. J Drug Target. 2019;27(10):964–77.
15. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595–608.
16. Pal, Rahul, et al. "Chitosan: as highly potential biopolymer obtainable in several advance drug delivery systems including biomedical applications." *Environmental science* 3.4 (2023).
17. Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kivipelto M. The amyloid β pathway in Alzheimer's disease. Mol Psychiatry. 2021;26:5378–90.
18. Niu X, Zhang J, Gao F. Nanocarriers: powerful vehicles to overcome blood–brain barrier. J Drug Target. 2019;27(10):964–77.
19. Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17:5–21.
20. Faiyaz M, Singh H, Gupta U, Kesharwani P. Nanomaterials in Alzheimer's disease treatment: a comprehensive review. Front Biosci Landmark. 2021;26:196–223.
21. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358–72.
22. Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. 2019;20(3):148–60.
23. Jalili C, Shafiee N, Yousefpour P, Hosseinzadeh R, Shabani L. Brain targeting nanocarriers loaded with resveratrol in Alzheimer's therapy: enhanced delivery and therapeutic outcome. J Nanobiotechnol. 2023;21(1):45.
24. Zlokovic BV. The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2):178–201.
25. Sweeney MD, Sagare AP, Zlokovic BV. Blood–brain barrier breakdown in Alzheimer's disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133–50.
26. Rakhi Mishra, Rahul Pal, Zuber Khan, Subhashree Sahoo, Himmat Singh Chawra, Dinesh Kumar, Solid Lipid Nanoparticles (SLNPs): A State-of-the-Art Formulation Strategy and their Applications against Tuberculosis (TB) and Analgesic Effects,

Nanoscience & Nanotechnology-Asia; Volume 15, Issue 3, Year 2025, e22106812379362. DOI: 10.2174/0122106812379362250602075954
27. Wang K, Li W, Wang Z. Nanocarrier-based targeted drug delivery for Alzheimer's disease. Int J Nanomedicine. 2025;20:1381–403.
28. Brambilla D, Verpillot R, Le Droumaguet B, Nicolas J, Taverna M, Kóňa J, Couvreur P. Lipid-based nanocarriers for central nervous system targeting: a promising approach for Alzheimer's therapy. Adv Drug Deliv Rev. 2020;148:291–306.
29. Gupta, Upmaniu, Sourabh Kosey, and Rahul Pal. "Advancements in Nanotechnology-Based Targeted Drug Delivery Systems for Glioblastoma Chemotherapy: A Comprehensive Review." *Journal of Drug Delivery Science and Technology* (2025): 107181.
30. Kannan S, Dai H, Navath RS, Balakrishnan B, Jyoti A, Janisse J, et al. Dendrimer-based therapy for neuroinflammation in Alzheimer's disease. Biomaterials. 2014;35(9):2573–83.
31. Niu X, Zhang J, Gao F. Nanocarriers: powerful vehicles to overcome blood–brain barrier. J Drug Target. 2019;27(10):964–77.
32. Pal, Rahul, et al. "Nano Drug Delivery Carriers (Nanocarriers): A Promising Targeted Strategy in Tuberculosis and Pain Treatment." *Pharmaceutical Nanotechnology* (2025).
33. Wang K, Li W, Wang Z. Nanocarrier-based targeted drug delivery for Alzheimer's disease. Int J Nanomedicine. 2025;20:1381–403.
34. Demeule M, Currie JC, Bertrand Y, Che C, Nguyen T, Régina A, et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of Angiopep-2. J Neurochem. 2008;106(4):1534–44.
35. Faiyaz M, Singh H, Gupta U, Kesharwani P. Nanomaterials in Alzheimer's disease treatment: a comprehensive review. Front Biosci Landmark. 2021;26:196–223.
36. Rhea EM, Banks WA, Erickson MA. Insulin transport across the blood–brain barrier. Peptides. 2018;101:12–6.
37. Wang K, Li W, Wang Z. Nanocarrier-based targeted drug delivery for Alzheimer's disease. Int J Nanomedicine. 2025;20:1381–403.
38. Pal, Rahul, et al. "Niosomal as Potential Vesicular Drug Nano-carriers for the Treatment of Tuberculosis (TB)." *Nanoscience & Nanotechnology-Asia* 15.1 (2025): E22106812323829.
39. Kumar A, et al. Mechanisms of blood-brain barrier penetration by nanoparticles: a review. J Nanobiotechnol. 2020;18(1):1–15.
40. Zhang Y, et al. Receptor-mediated transcytosis of nanoparticles across the blood-brain barrier: a review. Front Neurosci. 2021;15:1–12.
41. Lee J, et al. pH-sensitive nanocarriers for targeted drug delivery in Alzheimer's disease. Adv Drug Deliv Rev. 2022;178:113–25.
42. Smith R, et al. Targeted delivery of therapeutic agents for the clearance of amyloid-beta in Alzheimer's disease. Neurotherapeutics. 2023;20(2):345–60.

43. Vasanth, S., et al. "Advancing Mitochondrial Health in Huntington Disease (HD): Small Molecule Therapies and Neurodegeneration." *Current aging science*.
44. Kumar A, et al. Polymeric nanoparticles for targeted delivery of anti-amyloid agents in Alzheimer's disease. J Control Release. 2021;330:123–35.
45. Pal, Rahul, et al. "The comprehensive review: Exploring future potential of nasopulmonary drug delivery systems for nasal route drug administration." *Journal of Drug Delivery and Therapeutics* 14.3 (2024): 126-136.
46. ClinicalTrials.gov. Ongoing clinical trials involving nanocarriers for Alzheimer's disease [Internet]. 2023 [cited 2025 Aug 29]. Available from: https://clinicaltrials.gov
47. Baker JR, et al. Regulatory challenges in the development of nanomedicines: a review. Nanomedicine. 2021;17:102–15.
48. Patel A, et al. Safety assessment of nanocarriers: current challenges and future perspectives. Front Pharmacol. 2022;13:1–15.